Status:
RECRUITING
Role of Caveolin 1 (CAV-1) Deficiency in Response to Glucagon-like Peptide 1 (GLP-1) Receptor Agonist Treatment
Lead Sponsor:
Brigham and Women's Hospital
Collaborating Sponsors:
Charles A. King Trust Postdoctoral Fellowship Program
Conditions:
Overweight and Obesity
Eligibility:
All Genders
18+ years
Brief Summary
Obesity has become an important public health issue that leads to insulin resistance, diabetes, hypertension, dyslipidemia, and cardiovascular diseases. Although weight loss with calorie restriction a...
Detailed Description
Obesity is a chronic, multifactorial, and relapsing disease with an increasing prevalence that leads to insulin resistance, diabetes mellitus, hypertension, dyslipidemia, and cardiovascular diseases. ...
Eligibility Criteria
Inclusion
- Age ≥18 years, body mass index (BMI) ≥30.0 kg/m2 or ≥27.0 kg/m2 with the presence of at least one of the following weight-related comorbidities (treated or untreated): hypertension, prediabetes, dyslipidemia, obstructive sleep apnea,
- Normal screening laboratory values,
- Systolic BP \< 160 mmHg and diastolic BP \< 95 mmHg as determined from measurement during screening, using a random-zero device in the clinic and normal electrocardiogram, use of anti-hypertensive medications will be allowed except for mineralocorticoid receptor antagonists.
Exclusion
- Diabetes mellitus,
- Treatment with a glucose-lowering agent(s) or anti-obesity medication within 90 days of screening,
- Treatment with a GLP-1 receptor agonist within 180 days,
- Current treatment with beta-blocker, or steroids,
- Pregnancy,
- Personal history of pancreatitis,
- Personal history of cholelithiasis,
- Previous surgical obesity treatment,
- Personal or first-degree relative(s) history of multiple endocrine neoplasia type 2 or medullary thyroid carcinoma,
- Medical illness other than hypertension, prediabetes, obstructive sleep apnea, or dyslipidemia,
- Alcohol intake \>12 oz. per week,
- Tobacco, or recreational drug use
Key Trial Info
Start Date :
November 1 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
November 30 2026
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT06069622
Start Date
November 1 2023
End Date
November 30 2026
Last Update
December 10 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Brigham and Women's Hospital
Boston, Massachusetts, United States, 02115